DINAK 001
Alternative Names: DINAK-001Latest Information Update: 17 Jan 2023
Price :
$50 *
At a glance
- Originator DiNAQOR AG
- Class Gene therapies; Urologics
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Autosomal dominant polycystic kidney disease
Most Recent Events
- 02 Jan 2023 Preclinical trials in Autosomal dominant polycystic kidney disease in Switzerland (Parenteral) as of January 2023 (DiNAQOR pipeline, January 2023)
- 25 Aug 2022 DiNAQOR has a worldwide patent pending for loco-regional perfusion of a kidney
- 10 Jan 2022 DiNAQOR enters into a collaboration agreement with Children’s Medical Research Institute to develop AAV capsids for gene therapy delivery